ORMP Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 22:00):

Stats
Dagens volum	109 226
Gjennomsnittsvolum	150 793
Markedsverdi	94.81M
EPS	$0 ( 2024-03-04 )
Neste inntjeningsdato	( $0.0200 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	16.71
ATR14	$0.00700 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Reznick Yehuda	Buy	29 800	Common Stock
2024-04-01	Reznick Yehuda	Buy	0
2024-01-30	Aghion Daniel	Buy	3 750	Common Stock
2024-01-04	Kidron Miriam	Buy	295 500	Common Stock
2024-01-04	Kidron Nadav	Buy	329 000	Common Stock

INSIDER POWER
92.96
Last 95 transactions
Buy: 3 987 636 \| Sell: 392 701

Volum Korrelasjon

Lang: -0.24 (neutral)

Kort: -0.42 (neutral)

Signal:(47.179) Neutral

Oramed Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Oramed Pharmaceuticals Korrelasjon - Valuta/Råvare

0.01
( neutral )

-0.02
( neutral )

0.00
( neutral )

0.10
( neutral )

-0.74
( moderate negative )

-0.12
( neutral )

Oramed Pharmaceuticals Økonomi

Annual	2022
Omsetning:	$2.70M
Bruttogevinst:	$2.70M (100.00 %)
EPS:	$-0.970

FY	2022
Omsetning:	$2.70M
Bruttogevinst:	$2.70M (100.00 %)
EPS:	$-0.970

FY	2021
Omsetning:	$2.70M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.780

FY	2020
Omsetning:	$2.71M
Bruttogevinst:	$2.71M (100.00 %)
EPS:	$-0.560

Financial Reports:

No articles found.

Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.